Helsinki, Finland – Nanoform, an innovative nanoparticle medicine enabling company, has filed for GMP status with the Finnish Medicines Agency, FIMEA. The drug substance application for GMP clinical manufacture certification exemplifies its progress and growth in the last 12 months.
Nanoform has implemented a new Quality Management System in preparation for the submission, having appointed talented individuals with significant experience in Quality management and GMP manufacturing.
The certification will enable a seamless transition from non-GMP feasibility studies into GMP clinical manufacture, enabling clients to deliver NanoformedTM APIs to human patients in clinical trials. Achieving GMP status will further expedite international commercialization of Nanoform’s nanonization™ technology, which has the ability to double the number of drug compounds that reach clinical trials through improved dissolution rates and bioavailability enhancement. Building on the significant dose reduction capabilities recently evidenced by Nanoform in pK studies, the company is now well positioned to translate this value for patients globally.
As winners of the Excellence in Pharma Award for Formulation at the 2019 CPhI Awards, the application rounds off a successful year for Nanoform. The company aims to continue its rapid rate of progress in 2020 once the GMP license is awarded for clinical and commercial manufacture.
David Rowe, Nanoform’s Head of Manufacturing, said: “Filing for GMP status with FIMEA is a key milestone in Nanoform’s history. We look forward to working with our partners to deliver enhanced APIs to clinical trials and to help provide patients with faster access to innovative new treatments.”
Niklas Sandler, Nanoform’s Chief Technology Officer and Accountable Director, said: “We are delighted to end this exceptional year with our application for GMP clinical manufacture certification. By expanding our manufacturing capability, we are on course to increase the number of partners who benefit from our best-in-class nanoparticle engineering technology.”
Notes to the Editor
For further information, images and interview opportunities with Nanoform, please contact:
Shelley Farrar Stoakes at Notch Communications
+44 (0) 161 457 7230
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization™ services. The company’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) technology produces nanonized “designed-for-purpose” API particles, as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Nanoform’s unique nanonization™ technology provides novel opportunities in diverse value enhancing drug delivery applications.
For more information please visit http://www.nanoform.com